Seattle Children's Hospital Research Institute - Center for Global Infectious Disease Research

Orville Johnson

🇫🇷 France

8.6

Reviewed: October 2, 2023

• - Patient Engagement
• - 8 weeks August - September 2023
• - Clinical Research Organization

The patient engagement strategies implemented were impressive and led to a significant improvement in our recruitment rates. The team's experience in patient-centered approaches was evident and made a real difference.

Angie Morar

🇮🇹 Italy

9.3

Reviewed: March 12, 2024

• - Market Access Strategy
• - 6 weeks January - February 2024
• - Pharmaceutical Company

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Karla Wolff

🇮🇩 Indonesia

8.8

Reviewed: July 5, 2023

• - Biostatistical Design
• - 4 weeks May - June 2023
• - Research Institution

The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.

Tim Predovic

🇪🇸 Spain

9.2

Reviewed: February 15, 2023

• - Data Analysis
• - 4 weeks January 2023
• - Pharmaceutical Company

The team provided exceptional data analysis services, and the project was completed well within the timeline. Communication was clear and consistent, which made the whole process smooth. Highly recommended for anyone needing reliable clinical data management.

Marlon Lubowitz

🇨🇭 Switzerland

9.1

Reviewed: April 6, 2024

• - HTA Submission
• - 8 weeks February - March 2024
• - Biotech Company

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.

Stephanie Dickens

🇮🇹 Italy

9

Reviewed: June 18, 2023

• - Clinical Protocol Design
• - 6 weeks April - May 2023
• - Pharmaceutical Company

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Dr. Vicky Dibbert

🇩🇪 Germany

5.8

Reviewed: April 5, 2024

• - Biostatistical Design
• - 6 weeks February - March 2024
• - Research Institution

The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.

Andre Romaguera

🇳🇱 Netherlands

8.8

Reviewed: May 15, 2024

• - Companion Diagnostics Development
• - 16 weeks January - May 2024
• - Pharmaceutical Company

The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.

Dr. Clarence Waters

🇰🇷 South Korea

6.3

Reviewed: November 7, 2024

• - Stability Studies
• - 16 months July 2023 - November 2024
• - Pharmaceutical Company

The stability studies conducted were lacking in detail, and we had to perform additional validation to ensure the results were reliable. This added extra time and cost to the project. The team was responsive to feedback, but the initial work was subpar.